This was confirmed in sarcomas in a correlative analysis of SARC028, which established a correlation between the response to pembrolizumab and high densities of activated T cells (CD8+ CD3+ PD-1+) and an increased percentage of tumor-associated macrophages (TAM) expressing PD-L1 pre-treatment compared with non-responders [49]. This evidence concerns the gene CD274 and neoplasm.